Summary

The global CT/NG Testing Market was valued at approximately USD 1.85 billion in 2024 and is projected to expand at a robust compound annual growth rate (CAGR) of 8.60% over the forecast period from 2025 to 2035. CT/NG testing, which refers to the diagnostic processes for Chlamydia trachomatis and Neisseria gonorrhoeae infections, plays a critical role in sexual health management worldwide. These infections, if left untreated, can lead to severe reproductive health complications, driving the demand for precise and rapid diagnostic solutions. The market growth is propelled by rising awareness about sexually transmitted infections, government initiatives for sexual health screening, and technological advancements in diagnostic platforms.
The accelerating prevalence of sexually transmitted infections globally, combined with the growing adoption of advanced diagnostic technologies such as nucleic acid amplification tests (NAATs), polymerase chain reaction (PCR), and immunodiagnostics, has notably intensified the demand for CT/NG testing kits and analyzers. The shift towards point-of-care testing is transforming clinical workflows by enabling faster diagnosis and timely treatment, thereby reducing transmission rates and healthcare costs. Additionally, expanding healthcare infrastructure, especially in emerging economies, along with an increasing number of diagnostic laboratories and hospital-based testing facilities, fuels market expansion. However, the market growth might face headwinds due to reimbursement challenges and regulatory complexities in certain regions.
Geographically, North America dominates the CT/NG testing market, owing largely to its well-established healthcare infrastructure, widespread adoption of cutting-edge diagnostic technologies, and robust public health initiatives targeting STI control. The U.S., in particular, accounts for a significant share due to heightened government funding and awareness campaigns. Europe follows closely, with countries like Germany, the UK, and France leading due to comprehensive sexual health programs and strong laboratory networks. The Asia Pacific region is expected to witness the fastest growth during the forecast period, driven by increasing healthcare investments, rising prevalence of STIs, and improving diagnostic capabilities in populous nations such as China and India. Latin America and the Middle East & Africa are emerging markets with growing awareness and infrastructure development contributing to steady growth.
Major market players included in this report are:
• Hologic, Inc.
• Roche Diagnostics
• Abbott Laboratories
• Becton, Dickinson and Company
• Thermo Fisher Scientific Inc.
• Siemens Healthineers
• Quidel Corporation
• BD Diagnostics
• PerkinElmer, Inc.
• BioMérieux SA
• Ortho Clinical Diagnostics
• Gen-Probe, Inc.
• Alere Inc.
• Biomerica, Inc.
• Siemens Healthcare Diagnostics
Global CT/NG Testing Market Report Scope:
• Historical Data – 2023, 2024
• Base Year for Estimation – 2024
• Forecast period - 2025-2035
• Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope - Free report customization (equivalent up to 8 analysts’ working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study. The report also provides detailed information about crucial aspects, such as driving factors and challenges, which will define the future growth of the market. Additionally, it incorporates potential opportunities in micro-markets for stakeholders to invest, along with a detailed analysis of the competitive landscape and product offerings of key players. The detailed segments and sub-segments of the market are explained below:
By Product:
• Assays
• Kits
• Analyzers
By Test Type:
• Laboratory Testing
• Point-of-care Testing
By Technology:
• NAAT (Nucleic Acid Amplification Tests)
• PCR (Polymerase Chain Reaction)
• Immunodiagnostics
By End User:
• Diagnostic Labs
• Hospitals & Clinics
By Region:
North America
• U.S.
• Canada
Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe
Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific
Latin America
• Brazil
• Mexico
Middle East & Africa
• UAE
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa
Key Takeaways:
• Market Estimates & Forecast for 10 years from 2025 to 2035.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

ページTOPに戻る

Table of Contents

Table of Contents
Chapter 1. Global CT/NG Testing Market Report Scope & Methodology
1.1. Research Objective
1.2. Research Methodology
1.2.1. Forecast Model
1.2.2. Desk Research
1.2.3. Top Down and Bottom-Up Approach
1.3. Research Attributes
1.4. Scope of the Study
1.4.1. Market Definition
1.4.2. Market Segmentation
1.5. Research Assumption
1.5.1. Inclusion & Exclusion
1.5.2. Limitations
1.5.3. Years Considered for the Study
Chapter 2. Executive Summary
2.1. CEO/CXO Standpoint
2.2. Strategic Insights
2.3. ESG Analysis
2.4. Key Findings
Chapter 3. Global CT/NG Testing Market Forces Analysis
3.1. Market Forces Shaping The Global CT/NG Testing Market (2024-2035)
3.2. Drivers
3.2.1. Rising Prevalence of Sexually Transmitted Infections (STIs)
3.2.2. Growing Adoption of Advanced Diagnostic Technologies (NAATs, PCR, Immunodiagnostics)
3.3. Restraints
3.3.1. Reimbursement Challenges in Key Regions
3.3.2. Regulatory Complexities Impacting Market Entry and Growth
3.4. Opportunities
3.4.1. Shift Towards Point-of-Care Testing Enhancing Rapid Diagnosis
3.4.2. Expansion of Healthcare Infrastructure in Emerging Economies
Chapter 4. Global CT/NG Testing Industry Analysis
4.1. Porter’s 5 Forces Model
4.1.1. Bargaining Power of Buyer
4.1.2. Bargaining Power of Supplier
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Porter’s 5 Force Forecast Model (2024-2035)
4.3. PESTEL Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.3.5. Environmental
4.3.6. Legal
4.4. Top Investment Opportunities
4.5. Top Winning Strategies (2025)
4.6. Market Share Analysis (2024-2025)
4.7. Global Pricing Analysis And Trends 2025
4.8. Analyst Recommendation & Conclusion
Chapter 5. Global CT/NG Testing Market Size & Forecasts by Product 2025-2035
5.1. Market Overview
5.2. Assays
5.3. Kits
5.4. Analyzers
Chapter 6. Global CT/NG Testing Market Size & Forecasts by Test Type 2025-2035
6.1. Market Overview
6.2. Laboratory Testing
6.3. Point-of-care Testing
Chapter 7. Global CT/NG Testing Market Size & Forecasts by Technology 2025-2035
7.1. Market Overview
7.2. NAAT (Nucleic Acid Amplification Tests)
7.3. PCR (Polymerase Chain Reaction)
7.4. Immunodiagnostics
Chapter 8. Global CT/NG Testing Market Size & Forecasts by End User 2025-2035
8.1. Market Overview
8.2. Diagnostic Labs
8.3. Hospitals & Clinics
Chapter 9. Global CT/NG Testing Market Size & Forecasts by Region 2025-2035
9.1. North America
9.1.1. U.S.
9.1.2. Canada
9.2. Europe
9.2.1. UK
9.2.2. Germany
9.2.3. France
9.2.4. Spain
9.2.5. Italy
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. India
9.3.3. Japan
9.3.4. Australia
9.3.5. South Korea
9.3.6. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.5. Middle East & Africa
9.5.1. UAE
9.5.2. Saudi Arabia
9.5.3. South Africa
9.5.4. Rest of Middle East & Africa
Chapter 10. Competitive Intelligence
10.1. Top Market Strategies
10.2. Hologic, Inc.
10.2.1. Company Overview
10.2.2. Key Executives
10.2.3. Company Snapshot
10.2.4. Financial Performance (Subject to Data Availability)
10.2.5. Product/Services Port
10.2.6. Recent Development
10.2.7. Market Strategies
10.2.8. SWOT Analysis
10.3. Roche Diagnostics
10.4. Abbott Laboratories
10.5. Becton, Dickinson and Company
10.6. Thermo Fisher Scientific Inc.
10.7. Siemens Healthineers
10.8. Quidel Corporation
10.9. BD Diagnostics
10.10. PerkinElmer, Inc.
10.11. BioMérieux SA
10.12. Ortho Clinical Diagnostics
10.13. Gen-Probe, Inc.
10.14. Alere Inc.
10.15. Biomerica, Inc.
10.16. Siemens Healthcare Diagnostics